Expression Status and Potential Therapeutic Value of M6A in Autism Spectrum Disorder

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Autism Spectrum Disorder (ASD), a neurodevelopmental disorder, is characterized by social deficits, repetitive behaviors, and restricted interest. In this study, the objective was to examine variations in m6A-modified gene expression among patients with ASD and to assess their correlation with immune cell infiltration. Gene expression data obtained from the Gene Expression Omnibus (GEO) database were processed using the Limma package to identify differentially expressed genes. Molecular m6A methylation regulator subtypes were constructed using ConsensusClusterPlus, and hub m6A regulators were identified using Least Absolute Shrinkage and Selection Operator (LASSO) regression and Support Vector Machine-Recursive Feature Elimination (SVM-RFE). Protein-protein interaction networks were established using starBase2.0 and depicted using Cytoscape.In total, 6,277 differentially expressed genes were identified. Notably, m6A regulators displayed significant differential expression in samples from patients with ASD. LASSO and SVM-RFE analyses underscored WTAP and RBM15 as key autistic-associated elements. These results indicate that WTAP and RBM15 modifications significantly contribute to ASD pathogenesis by influencing gene expression profiles and variations in the immune microenvironment. Deciphering the mechanism of action of ASD has revealed actionable strategies for precise therapy development.

Article activity feed